Navigating Your Toughest Price And Market Access Challenges

NAVLIN by EVERSANA is a single, integrated platform that combines data, software and insights to answer your most challenging price and access questions.

We help you plan and evaluate strategies to achieve success in U.S. and global markets.

Explore NAVLIN

Comprehensive. Intuitive. Integrated.

Comprehensive Ecosystem

NAVLIN by EVERSANA delivers a single easy-to-use platform that integrates highly accurate price and access data, software and insights to drive exponential value in the life sciences.

NAVLIN Price & Access Data

NAVLIN Price & Access Data is the industry’s most comprehensive, highly accurate database of global price and market access intelligence, providing the right answers to the right questions to inform your strategy at launch and beyond.

NAVLIN Price & Access Data

NAVLIN Price & Access Software

NAVLIN Price & Access Software provides the most accurate and comprehensive enterprise software solution to address global pricing challenges for pharmaceutical manufacturers.

NAVLIN Price & Access Software

NAVLIN Insights

NAVLIN Insights delivers the most innovative market research solutions for biopharmaceutical companies’ business questions from pipeline to loss of exclusivity.

NAVLIN Insights

NAVLIN Daily

NAVLIN Daily keeps you up to date and informed by connecting the dots on how the day’s biggest stories affect your business. Experience global price and market access news without all the noise.

NAVLIN Daily

NAVLIN Revenue Management

NAVLIN Revenue Management brings together all critical revenue management operations, along with the power of NAVLIN Price & Access Data, to deliver efficient, intuitive, accurate and compliant tracking and reporting – all in one innovative & integrated digital platform.

NAVLIN Revenue Management

Comprehensive Ecosystem

NAVLIN by EVERSANA delivers a single easy-to-use platform that integrates highly accurate price and access data, software and insights to drive exponential value in the life sciences.

NAVLIN Price & Access Data

NAVLIN Price & Access Data

NAVLIN Price & Access Data is the industry’s most comprehensive, highly accurate database of global price and market access intelligence, providing the right answers to the right questions to inform your strategy at launch and beyond.

NAVLIN Price & Access Software

NAVLIN Price & Access Software

NAVLIN Price & Access Software provides the most accurate and comprehensive enterprise software solution to address global pricing challenges for pharmaceutical manufacturers.

NAVLIN Insights

NAVLIN Insights

NAVLIN Insights delivers the most innovative market research solutions for biopharmaceutical companies’ business questions from pipeline to loss of exclusivity.

NAVLIN Daily

NAVLIN Daily

NAVLIN Daily keeps you up to date and informed by connecting the dots on how the day’s biggest stories affect your business. Experience global price and market access news without all the noise.

NAVLIN Revenue Management

NAVLIN Revenue Management

NAVLIN Revenue Management brings together all critical revenue management operations, along with the power of NAVLIN Price & Access Data, to deliver efficient, intuitive, accurate and compliant tracking and reporting – all in one innovative & integrated digital platform.

Experience the
NAVLIN difference

650+
Global sources monitored daily for price, HTA, policy and tender data
+99%
Accuracy of real-time reimbursement, HTA and tender data
<24
hours Speed of updates made from time of publication
4,000+
Medical and pharmacy decision-making executives included in NAVLIN Insights survey panels
24x7
Continuous operations and support
99.5%
Customer satisfaction with market research insights
Real quotes from real clients

Client Delight

This is an amazing tool. The data quality, insights, and user-friendliness are far superior to any other pricing database I’ve used in my career.

Enric Muñoz

Sr. Director, Global Strategic Pricing Head, Takeda

To say thank you seems so trivial. I really appreciate all the hard work and time that you all have invested.

Sr. Director, Global Strategic Pricing Head, Takeda

My team literally could not do what they do without this solution.

Sr. Director, Market Access

Intelligent, intuitive, insightful, helpful, and responsive!

US Payer & Channel Access, Pfizer

NAVLIN Daily News

Checkout Today’s News

European Parliament Backs Revised Pharma Legislation…

The European Parliament has adopted the revisions to EU pharmaceutical legislation, cementing the biggest policy reform in this area in two decadesThe terms for Regulatory Data Protection have been altered from the original proposal, as have the nuances around launch conditionality and transferrable exclusivity vouchers granted for antimicrobials. Though the amendments to the reform have been generally well-received, industry associations like EUCOPE and EFPIA still have areas of particular concernThe legislation is not expected to be negotiated until 2026 and will likely not be in effect until 2028. The main concern for policymakers now is aligning these changes with the goal of enhancing Europe's competitiveness and resilience

LAST WEEK IN REVIEW

The Pharmaceutical Research and Manufacturers of America (PhRMA) has embraced Japan's FY2024 drug pricing reform. The reform passed in late 2021 is set to roll out from April 2024, and is considered a positive step towards balancing new drug pricing, the cost of innovation, and healthcare spendingJiuyuan Gene’s product could become China’s first biosimilar referencing Novo Nordisk’s diabetes and weight-loss drug Ozempic (semaglutide).The European Access Academy (EAA), as part of the European Commission's HTA Stakeholder Network, has issued a commentary paper on the first Implementation Acts (IA) draft regarding the European Regulation on Health Technology Assessment (EU HTAR)

Germany Passes Medical Research Act, Maintains…

The German federal government's cabinet has approved the Medical Research Act draft with a few minor changes. Notably, the controversial move to enable confidential payment amounts for new medicines was retained in the final draftThe move on confidential prices has raised concerns. Critics from industry and insurers believe it could potentially lead to billions in extra costs every year without any added value for care. There are also fears that this could significantly increase drug prices in other European countries and add to the bureaucratic burden for insurance companiesThe AOK Federal Association has suggested having an "interim price" for medicines from the day after approval. This would replace the free list price and be retroactively set against a fixed reimbursement amount after nine months. The focus, they believe, should be on maintaining high-quality drug supply at affordable prices and not on jeopardizing proven pricing mechanisms

Meet us at WODC 2024!

We are pleased to announce that NAVLIN Daily is an official media partner with the World Orphan Drug Congress (WODC) USA, taking place April 23-25, 2024, at the Boston Convention and Exhibition Center in Boston, MassachusettsThe event convenes leading pharmaceutical and biotech companies, government and regulatory authorities, patient advocacy groups, payers, investors and solution providers to meet and brainstorm ways to advance orphan drug development and improve access to life-saving therapiesAs a valued NAVLIN customer, you can use our NAVLIN50 registration discount code for an exlusive 50% discount

Pharma USA 2024: Linking Long-term Durability to…

At Pharma USA 2024, Lukasz Jarzyna, of Alexion, worried about small U.S. payers in the cell & gene therapy space: “Maybe they have zero patients one year, maybe they have a whole family under the plan that's diagnosed,” adding that a stop loss arrangement could help Meanwhile, Medicaid Best Price complicates value-based agreements (VBAs), but the executive said work is underway to define how such agreements will functionPayers are also developing tracking systems for patients who keep switching plans since U.S. patients switch often, noted Jarzyna

Pharma USA 2024: Partnering with Patients and…

In the cell and gene therapy (CGT) space, access to treatments is limited, and companies need to work harder to reach out to patient populations and gain insights while seeking ways to raise the quality of point of contact data, panelists saidIt was noted that small molecules and CGT need to be studied differently, as new and unexpected metrics are often needed for CGTFive or ten years out, long-term follow-up opportunities could look very different from existing data registries, said Jason Lott, from Bayer, who worries about duplication and a lack of economies of scale

Pharma USA 2024: Bringing CAR T-Cell Therapies Closer…

Today, just two in ten patients have access to these therapies, lamented Cindy Perettie of Kite, Gilead, at Pharma USA 2024On the advancement of CAR T therapies, Jeff Patton of One Oncology noted, “You really need to educate payers and health systems. Tell them this is coming and this is big. I don't think they know how big it's going to be” Patton predicts that community clinics will become more proficient than academic centers at delivering CAR T care because they will see more patients

Pharma USA 2024: Leveraging Lessons for Cell & Gene…

In cell and gene therapy (C&G) development, Heidi Zhang, from Tune Therapeutics, said it is important to focus on patients, iron out any small complications in trials, and be mindful of unique CMC challenges “Naturally, digitalization is an extension of patient engagement,” said Robert Sexton, of Mustang Bio, “Digital can be the backbone of successfully scaling up”The work of many stakeholders is needed to ensure service accuracy in the C&G space, noted Li Pan, of Johnson & Johnson, and each stakeholder needs to be engaged with and supported

Pharma USA 2024: Building Capabilities to Support Gene…

A talk at Pharma USA 2024 featured executives from Astellas, which is one of few companies with end-to-end gene therapy capabilitiesIn gene therapy development, patients should be engaged in a different way where they are seen as partners and patient outcomes are a true focus, explained Megan Sullivan of Astellas.Sullivan noted that regulators are asking the industry to help them understand how gene therapies are different, which is a change from the past

Pharma USA 2024: Sustainable Innovation & Access in…

During Reuters Pharma USA 2024, Chris Mancill, of Bristol Myers Squibb, said it's important not to hyper-focus on the Inflation Reduction Act (IRA) as other important developments are in the worksOn the limited uptake of value-based agreements, “If we can go beyond randomized control trials (RCTs) and use RWE to show reduced cost of care, that would help,” suggested Chris Dallas-Feeney, Life Sciences Market Access Advisor The panelists expressed mixed opinions on patient-reported outcomes (PROs), which have received some support from payers but lack structure in various ways

Connect With Our Team Of Global Experts

Contact Us

Feel free to get in touch with us via email, live chat, or schedule a meeting!